Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 14, 2016

Primary Completion Date

June 25, 2018

Study Completion Date

October 31, 2024

Conditions
Niemann-Pick Disease, Type C
Interventions
DRUG

arimoclomol

DRUG

Placebo

Trial Locations (14)

2100

University Hospital Copenhagen (Rigshospitalet), Copenhagen

33100

"Azienda Ospedaliero-Universitaria Santa Maria della Misericordia di Udin", Udine

55131

Villa Metabolica, Universitätsmedizin Mainz, Mainz

55905

Mayo Clinic Children's Center, Rochester

80337

Dr. von Haunersches Kinderspital der Universität München, Munich

94609

UCSF Benioff Children's Hospital Oakland, Oakland

34295 Montpellier Cedex 5

CHU de Montpellier, Montpellier

75571 PARIS Cedex 12

Hôpital Trousseau, Paris

00165

Ospedale Pediatrico Bambino Gesù, Rome

04-730

The Children´s Memorial Istitute Warsaw, Warsaw

08035

Hospital Vall D'Hebron, Barcelona

CH-3010

INSELSPITAL University Hospital Bern, Bern

B4 6NH

Birmingham Children's Hospital, Birmingham

WC1N 3JH

Great Ormond Street Hospital, London

All Listed Sponsors
lead

ZevraDenmark

INDUSTRY

NCT02612129 - Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C | Biotech Hunter | Biotech Hunter